Organization
Breast Center, Yuncheng Central Hospital, Yuncheng, China
3 abstracts
Abstract
Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.Org: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Breast Surgery, Jiangxi Cancer Hospital, Nanchang, China, Hunan Cancer Hospital, Changsha, China, Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China,
Abstract
Bireociclib plus fulvestrant for advanced HR+/HER2- breast cancer progressing after endocrine therapy: Interim analysis of a phase 3 trial (BRIGHT-2).Org: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Harbin Medical University Cancer Hospital, Harbin, China, Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, Department of Medical Oncology, Hunan Cancer Hospital, Changsha, China,
Abstract
A phase 1 study of liposomal irinotecan in patients with advanced breast cancer.Org: Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Harbin Medical University Cancer Hospital, Harbin, China, Department of Breast, Henan Cancer Hospital, Zhengzhou, China, Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China,